• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.

作者信息

Schlechte W, Murano G, Boyd D

机构信息

Department of Pharmacology, Bristol-Baylor Laboratory, Baylor College of Medicine, Houston, Texas 77030.

出版信息

Cancer Res. 1989 Nov 1;49(21):6064-9.

PMID:2551498
Abstract

The relevance of urokinase receptors to urokinase-mediated laminin degradation was investigated in cultured colon cancer. Six colon cancer cell lines degraded laminin in a plasminogen-dependent manner. The ability of the individual cell lines to cleave the glycoprotein correlated well (r2 = 0.9242) with the amount of urokinase recovered from the cell surface by a mild acid treatment. A radioreceptor assay indicated that colon cancer cells most active in degrading the laminin, possessed the largest number of urokinase receptors. Moreover, acid treatment which depletes the receptors of endogenous plasminogen activator augmented the specific binding of radioactive urokinase to the colon cancer cells by 12-200%. A cell line (HCT 116) which displayed 1.1 x 10(5) receptors/cell the majority of which were occupied with endogenous urokinase was selected and the effects of a urokinase receptor antagonist on laminin degradation determined. The peptide antagonist reduced laminin turnover by 60-80%. Morphological observations were consistent with these findings. Plasminogen-treated HCT 116 cells retracted from the culture dish and many cells were observed in the culture medium. This effect could be largely reversed by simultaneous treatment with the peptide antagonist. A poor correlation was found between laminin degradation and soluble urokinase (r2 = 0.1074). These data strongly argue for a role of the urokinase receptor in facilitating the action of the plasminogen activator in colon cancer.

摘要

相似文献

1
Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.
Cancer Res. 1989 Nov 1;49(21):6064-9.
2
Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer.
Cancer Res. 1991 Jul 15;51(14):3690-5.
3
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.培养的结肠癌细胞对细胞外基质的侵袭:对尿激酶受体表达的依赖性。
Cancer Commun. 1990;2(5):173-9.
4
Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.
Cancer Res. 1989 Feb 15;49(4):816-20.
5
Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line.检测表皮生长因子对人结肠癌细胞系中尿激酶产生及纤溶酶原激活物受体表达的影响。
Cancer Res. 1989 May 1;49(9):2427-32.
6
Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
Cancer Res. 1988 Jun 1;48(11):3112-6.
7
Determination of the effects of epidermal growth factor on urokinase secretion and urokinase receptor display in a well-differentiated human colon carcinoma cell line.表皮生长因子对一种高分化人结肠癌细胞系中尿激酶分泌及尿激酶受体表达影响的测定
Cancer Res. 1989 Apr 15;49(8):1948-53.
8
Urokinase-dependent proteolysis in cultured colon cancer is directed by its receptor.培养的结肠癌细胞中依赖尿激酶的蛋白水解作用由其受体引导。
Semin Thromb Hemost. 1991 Jul;17(3):225-30. doi: 10.1055/s-2007-1002613.
9
Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas.层粘连蛋白-5是某些人类癌症中侵袭性癌细胞的标志物,并且在结肠腺癌的萌芽癌细胞中与尿激酶型纤溶酶原激活物受体共表达。
Cancer Res. 1995 Sep 15;55(18):4132-9.
10
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.人Co115结肠癌细胞增强组织型纤溶酶原激活剂介导的层粘连蛋白降解。
J Cell Physiol. 1994 Nov;161(2):285-92. doi: 10.1002/jcp.1041610213.

引用本文的文献

1
Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025.上皮-间质转化(EMT)与癌症转移:2025年方法与实验模型的现状
Mol Cancer. 2025 Jun 7;24(1):167. doi: 10.1186/s12943-025-02338-2.
2
uPAR: An Essential Factor for Tumor Development.尿激酶型纤溶酶原激活物受体:肿瘤发展的关键因素
J Cancer. 2021 Oct 17;12(23):7026-7040. doi: 10.7150/jca.62281. eCollection 2021.
3
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.
肿瘤相关基质细胞中尿激酶型纤溶酶原激活物受体(uPAR)的表达与结直肠癌患者预后相关:一项组织芯片研究
BMC Cancer. 2014 Apr 17;14:269. doi: 10.1186/1471-2407-14-269.
4
Characterization and function of human Ly-6/uPAR molecules.人 Ly-6/uPAR 分子的特征和功能。
BMB Rep. 2012 Nov;45(11):595-603. doi: 10.5483/bmbrep.2012.45.11.210.
5
The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?尿激酶受体(u-PAR)——肿瘤细胞休眠与骨髓微小残留病之间的联系?
APMIS. 2008 Jul-Aug;116(7-8):602-14. doi: 10.1111/j.1600-0463.2008.00997.x.
6
The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection.分枝杆菌感染期间纤溶系统在播散和基质蛋白沉积中的作用
Am J Pathol. 2003 Aug;163(2):517-31. doi: 10.1016/S0002-9440(10)63680-2.
7
Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene.转基因小鼠展示了尿激酶受体基因组织特异性表达的新启动子区域。
Am J Pathol. 2003 Aug;163(2):453-64. doi: 10.1016/S0002-9440(10)63675-9.
8
Targeted disruption of the K-ras oncogene in an invasive colon cancer cell line down-regulates urokinase receptor expression and plasminogen-dependent proteolysis.在一种侵袭性结肠癌细胞系中对K-ras癌基因进行靶向破坏可下调尿激酶受体表达和纤溶酶原依赖性蛋白水解作用。
Br J Cancer. 1999 Aug;80(12):1884-91. doi: 10.1038/sj.bjc.6690616.
9
Evidence that platelet and tumour heparanases are similar enzymes.血小板和肿瘤乙酰肝素酶是相似酶类的证据。
Biochem J. 1999 Sep 1;342 ( Pt 2)(Pt 2):361-8.
10
Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist.
Clin Exp Metastasis. 1998 Jan;16(1):9-20. doi: 10.1023/a:1006503816792.